Science.Online
Search
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Keyword index :: hyd bis kel :: I/D polymorphism - IGF-II Ibritumomab tiuxetan

Items for "Ibritumomab tiuxetan"

Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives

90Y-ibritumomab tiuxetan (Zevalin) is currently approved for radioimmunotherapy of patients with relapsed or refractory follicular non-Hodgkins lymphoma pretreated with rituximab...

Keywords: Ibritumomab-Tiuxetan, Zevalin®, Yttrium-90, Radioimmuntherapie, Aktivimeter, Strahlenschutz

01/2005 | Nuklearmedizin, Schattauer
Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial

Aim of this study was the assessment of the radiation exposure from preparation and application of 90Y-Zevalin, the measurement of the dose rate at the patient, the exposure of family members as well as the determination of the activity concentration in urine of patients...

Keywords: Ibritumomab Tiuxetan, Zevalin, 90Y, ß - -Strahlung, Bremsstrahlung, Radioimmuntherapie, Strahlenexposition, Hautdosis, Strahlenschutz

01/2006 | Nuklearmedizin, Schattauer